Biren Amin

Piper Sandler | Healthcare

Biren Amin is an analyst from Piper Sandler specializing in the Healthcare sector. Ranked #2016 out of 4650 analysts, they have issued 22 stock ratings with a success rate of 70.69% and an average return of 25.18%.

Biren Amin has a well-established track record, with 22 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 70.69% and an average return of 25.18%, underscoring their expertise and ability to identify winning opportunities for investors.

#2016

Out of 4650

22

Total Ratings

+70.69%

Success Rate

+25.18%

Average Return

Recent Ratings Analysis

LENZ

May 12, 2026

Target

$12.00

Current

$7.91

Performance

0.00%

Biren Amin rated LENZ as Neutral on May 12, 2026, setting a price target of 12. The Hold stance appears justified, as shares hovered around 7.91 with a 0.00% move.

ACRS

May 05, 2026

Target

$11.00

Current

$4.88

Performance

2.74%

On May 05, 2026, ACRS was given a Overweight rating by Biren Amin, with a target price of 11. The stock traded sideways with a 2.74% move, keeping the bullish thesis unresolved.

REGN

Mar 31, 2026

Target

$875.00

Current

$723.41

Performance

-6.37%

REGN received a Overweight rating from Biren Amin on Mar 31, 2026, aiming for 875. The rating hasn’t played out as hoped, with the stock trading 6.37% below expectations.

CNTX

Mar 24, 2026

Target

$7.00

Current

$2.48

Performance

-22.01%

On Mar 24, 2026, Biren Amin published a Overweight outlook on CNTX, with a target of 7. Market action contradicted the Buy thesis, as shares slipped to 2.48.

IMTX

Mar 16, 2026

Target

$18.00

Current

$11.39

Performance

16.11%

Biren Amin on Mar 16, 2026 assigned IMTX a Buy rating, with a price target of 18. The Buy call aligned well with market performance, producing a gain of 16.11%.

ALLO

Mar 13, 2026

Target

$8.00

Current

$2.30

Performance

-4.17%

On Mar 13, 2026, Biren Amin reaffirmed ALLO with a Overweight rating, targeting 8. Market indecision has kept the 8 target in a holding pattern.

KYMR

Feb 26, 2026

Target

$140.00

Current

$83.55

Performance

-12.08%

KYMR was rated Overweight by Biren Amin on Feb 26, 2026, with a price objective of 140. This case shows how bullish projections can fail, with the stock now below 83.55.

OKYO

Feb 20, 2026

Target

$7.00

Current

$1.62

Performance

-4.71%

On Feb 20, 2026, Biren Amin initiated coverage on OKYO with a Overweight rating and target of 7. Neutral price movement of -4.71% leaves room for interpretation.

CATX

Feb 19, 2026

Target

$16.00

Current

$3.77

Performance

-33.27%

Biren Amin issued a Overweight recommendation for CATX on Feb 19, 2026, price target set at 16. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

IRD

Nov 25, 2025

Target

$7.00

Current

$5.18

Performance

161.62%

On Nov 25, 2025, IRD was evaluated by Biren Amin, who gave a Overweight rating and target of 7. This case illustrates how a timely bullish rating can translate into tangible gains of 161.62%.

AAPG

Nov 05, 2025

Target

$48.00

Current

$21.16

Performance

-35.70%

Biren Amin rated AAPG as Overweight on Nov 05, 2025, setting a price target of 48. The stock has underperformed, dropping 35.70% despite the bullish target of 48.

SRPT

Oct 30, 2025

Target

$16.00

Current

$19.13

Performance

-17.72%

On Oct 30, 2025, SRPT was given a Neutral rating by Biren Amin, with a target price of 16. The rating provided protection from downside risk as the stock fell to 19.13.

BBIO

Oct 30, 2025

Target

$98.00

Current

$65.95

Performance

4.07%

BBIO received a Overweight rating from Biren Amin on Oct 30, 2025, aiming for 98. Price action was muted, as shares hovered around 65.95 despite the bullish outlook.

OCUL

Oct 03, 2025

Target

$31.00

Current

$9.16

Performance

-19.72%

On Oct 03, 2025, Biren Amin published a Overweight outlook on OCUL, with a target of 31. Market action contradicted the Buy thesis, as shares slipped to 9.16.

MNPR

Sep 25, 2025

Target

$95.00

Current

$61.35

Performance

-20.78%

Biren Amin on Sep 25, 2025 assigned MNPR a Overweight rating, with a price target of 95. The call has struggled to gain traction, with shares losing 20.78%.

CNTA

Mar 31, 2025

Target

$38.00

Current

$39.61

Performance

175.45%

On Mar 31, 2025, Biren Amin reaffirmed CNTA with a Overweight rating, targeting 38. The recommendation was supported by strong follow-through as the stock rose from 39.61 to 39.61.

ELEV

Mar 21, 2025

Target

$0.70

Current

$0.36

Performance

21.63%

ELEV was rated Neutral by Biren Amin on Mar 21, 2025, with a price objective of 0.7. Despite caution, upside momentum rewarded risk-takers with gains to 0.365.

CMPX

Feb 19, 2025

Target

$12.00

Current

$1.87

Performance

-44.67%

On Feb 19, 2025, Biren Amin initiated coverage on CMPX with a Overweight rating and target of 12. The Buy call has yet to be validated as shares remain 10.13 away from the target.

VKTX

Feb 06, 2025

Target

$71.00

Current

$31.32

Performance

-0.45%

Biren Amin issued a Overweight recommendation for VKTX on Feb 06, 2025, price target set at 71. The target of 71 remains in play, though confirmation will depend on future moves.

CRGX

Jan 30, 2025

Target

$4.00

Current

$4.47

Performance

31.86%

On Jan 30, 2025, CRGX was evaluated by Biren Amin, who gave a Neutral rating and target of 4. Investors who stayed in despite the Hold saw upside of 31.86%.

CRBP

Dec 02, 2024

Target

$35.00

Current

$11.43

Performance

-35.93%

Biren Amin rated CRBP as Overweight on Dec 02, 2024, setting a price target of 35. The stock has underperformed, dropping 35.93% despite the bullish target of 35.

AGEN

Jul 19, 2024

Target

$3.00

Current

$3.44

Performance

-42.57%

On Jul 19, 2024, AGEN was given a Hold rating by Biren Amin, with a target price of 3. The rating provided protection from downside risk as the stock fell to 3.44.

SLDB

Jun 21, 2024

Target

$20.00

Current

$7.72

Performance

19.50%

SLDB received a Overweight rating from Biren Amin on Jun 21, 2024, aiming for 20. Momentum has favored the Buy call, with shares climbing from 7.72 to 7.72, rewarding those who trusted the recommendation.

Frequency Asked Questions

Who is Biren Amin?

Biren Amin is an analyst from Piper Sandler specializing in the Healthcare sector.

What is Biren Amin's success rate?

Biren Amin currently has a success rate of +70.69%.

How many ratings has Biren Amin issued?

Biren Amin has issued 22 stock ratings so far.

What is the average return of Biren Amin's calls?

Their stock ratings have generated an average return of +25.18%.

What is Biren Amin's ranking?

Biren Amin is ranked #2016 out of 4650 analysts.

What types of ratings does Biren Amin give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Biren Amin?

You can follow Biren Amin by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Biren Amin?

Their latest rating was a Hold on LENZ issued on 2026-05-12.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep